A novel and clinically validated optical biosensor enables rapid and quantitative serological testing of COVID-19

An innovative nano-biosensor for fast, quantitative and accurate COVID-19 serology, which achieves the high reliability of specialised laboratory analysis with the short times and simplicity of rapid self-tests, has been developed by a team of researchers led by Prof. Laura M. Lechuga, CSIC Research Professor and head of the ICN2 NanoBiosensors and Bioanalytical Applications Group, at the UAB.

Serological tests play an important role in the surveillance and management of epidemics or pandemics, as well as in acquired immunity studies. Currently, COVID-19 serology is performed by well-established immunoassay techniques, which provide high sensitivities, but require specialized laboratories with trained personnel and processing times of 3 to 48 hours. A much faster and easier method is the lateral flow assay— such as the rapid diagnostic tests sold in pharmacies. However, the latter are not fully reliable, as they exhibit only moderate sensitivity and specificity.

A team of researchers led by Prof. Laura M. Lechuga, CSIC Research Professor and head of the NanoBiosensors and Bioanalytical Applications Group at the Catalan Institute of Nanoscience and Nanotechnology (ICN2), at the UAB campus, has developed and extensively validated a novel serological nano-biosensor that provides a rapid (less than 15 minutes) identification and quantification of SARS-COV-2 antibodies in blood serum, without the need for sample pre-treatment and lengthy processing. It employs an optical sensing device based on a plasmonic technique that Prof. Lechuga’s group has been consolidating for years and has implemented for the diagnostics of diverse diseases and conditions –such as detection of cancer biomarkers, gluten ingestion or antibiotic allergy.

Extensive testing on clinical samples, provided by the Vall d'Hebron University Hospital and the Hospital Clínic of Barcelona–IDIBAPS during the first months of COVID-19 pandemic, was performed to prove the efficacy and reliability of this biosensor technology. In particular, 120 samples of serum were used, of which 100 from confirmed COVID-19 positive patients and 20 negative ones (collected prior to the outbreak of the pandemic). Comparative analyses with standard techniques and commercial lateral flow assays showed that this plasmonic biosensor technology outperforms well-established diagnostic methods, providing excellent sensitivity (99%) and specificity (100%).

Such remarkable accuracy and the short operation times (the result is available in less than 15 minutes) make of this new biosensor an outstanding tool for rapid and reliable serological tests. Fast and quantitative serology is crucial for monitoring the evolution of the COVID-19 pandemic, managing patients’ hospitalization and placement in intensive care units and assessing the immunological status of individuals during vaccination campaigns and in the presence of emerging variants of the virus.

Since the read-out device is compact and the procedure can be automatized, this technology has also potential for point-of-care applications and could be introduced in doctors’ practices and pharmacies. In addition, the same technique can be employed for the detection of various substances in body fluids –such as gluten peptides, early cancer biomarkers, anticoagulant drugs, or antibiotic allergy antibodies — thus, for the diagnostics and monitoring of many diseases.

The readiness level of this technique is already very high and their developers are committed to achieve a fast technology transfer to industry, in order to introduce this new biosensor device both in the clinical environment and in decentralised settings. Watch this animation illustrating how a portable read-out device with disposal cartridges would work.

The results of this study, carried out in the framework of the EU funded project CoNVaT, have been published in Analytical Chemistry. The research has been developed by Prof Lechuga’s group in collaboration with the Intensive Care and Clinical Microbiology Departments of the Vall d'Hebron University Hospital (Barcelona, Spain), the Department of Pneumology of the Hospital Clínic of Barcelona-IDIBAPS, and the Emerging Virus Unit of Aix-Marseille University (France). Senior researchers Dr Maria Soler and Dr M. Carmen Estévez are the corresponding authors, while PhD student Olalla Calvo-Lozano is the first author, having performed the optimization and validation of the system.

About the ICN2

The Institut Català de Nanociència i Nanotecnologia (ICN2) is dedicated to the development of knowledge, materials and devices in the wide field of health, energy, environment and the technologies of computers and communications. Its experience is in the nanoscale where new properties and interactions, as well as ways of using them in the daily life, are constantly being discovered. Amongst its goals are reuniting scientific personnel with different competences in the look for a better science, a better teaching and a higher impact on society, at the same time it explores new ways of interacting with local and global industries.

The institute was credited as a Centre d'Excel·lència Severo Ochoa in 2014 and the Ministerio de Ciencia, Innovación y Universidades renovated this prize in 2018. Amongst its patrons are the Generalitat de Catalunya, the Consejo Superior de Investigaciones Científicas (CSIC) and the Universitat Autònoma de Barcelona (UAB), where the institute is placed. ICN2 is a CERCA centre and also one of the founding members of the Barcelona Institute of Science and Technology (BIST) and the European Graphene Flagship.

Reference article:

Olalla Calvo-Lozano, Miquel Sierra, Maria Soler, Maria Carmen Estévez, Luis Chiscano-Camón, Adolfo Ruiz-Sanmartin, Juan Carlos Ruiz-Rodriguez, Ricard Ferrer, Juan José González-López, Juliana Esperalba, Candela Fernández-Naval, Leticia Bueno, Ruben López-Aladid, Antoni Torres, Laia Fernández-Barat, Sarah Attoumani, Rémi Charrel, Bruno Coutard, and Laura M. Lechuga, Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation. Anal. Chem. 2022, 94, 2, 975–984. DOI: 10.1021/acs.analchem.1c03850